EFEITOS TERAPÊUTICOS DOS AGONISTAS DO RECEPTOR DO GLP-1: UM ESTUDO DE REVISÃO

Felipe Moraes  Gonçalves; Flávia de Souza Araújo; Gustavo Fukuyama Barbosa; Caio Leonardo Zanatta  Presoto; Taiane Priscila  Gardizani

doi:10.69719/ros.v8.862

Autores

Felipe Moraes Gonçalves Centro Universitário de Adamantina - FAI https://orcid.org/0009-0000-1104-5843
Flávia de Souza Araújo Centro Universitário de Adamantina - FAI https://orcid.org/0009-0007-3137-5672
Gustavo Fukuyama Barbosa Centro Universitário de Adamantina - FAI https://orcid.org/0009-0004-4019-947X
Caio Leonardo Zanatta Presoto Centro Universitário de Adamantina - FAI https://orcid.org/0009-0004-8167-0010
Taiane Priscila Gardizani Centro Universitário de Adamantina - FAI https://orcid.org/0000-0002-3903-334X

DOI:

https://doi.org/10.69719/ros.v8.862

Palavras-chave:

Agonistas do receptor GLP-1, Ozempic, Semaglutida

Resumo

Os agonistas do receptor do peptídeo semelhante ao glucagon-1 (GLP-1) representam uma abordagem terapêutica inovadora para o manejo do diabetes mellitus tipo 2 (DM2) e outras doenças metabólicas, uma vez que atuam estimulando a secreção de insulina de maneira glicose-dependente. A partir do estudo de seu mecanismo de ação foi possível evidenciar benefícios em diferentes sistemas como endócrino, gastrointestinal, cardiovascular e renal. Dessa maneira, o presente estudo abordou os efeitos terapêuticos dos agonistas do receptor do GLP-1, com foco nos sistemas acima mencionados, com o propósito de sintetizar os principais resultados sobre o controle glicêmico e a prevenção de comorbidades para pacientes com DM2.

Referências

1. Yin WL, Bain SC, Min T. The effect of glucagon-like peptide-1 receptor agonists on renal outcomes in type 2 diabetes. Diabetes Ther. 2020;11(4):835-44. doi: 10.1007/s13300-020-00798-x. DOI: https://doi.org/10.1007/s13300-020-00798-x

2. Gómez-Huelgas R, Sanz-Cánovas J, Cobos-Palacios L, López-Sampalo A, Pérez-Belmonte LM. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: a treatment approach far beyond their glucose-lowering effect. Eur J Intern Med. 2022;96:26-33. doi: 10.1016/j.ejim.2021.11.008. DOI: https://doi.org/10.1016/j.ejim.2021.11.008

3. Greco EV, Russo G, Giandalia A, Viazzi F, Pontremoli R, De Cosmo S. GLP-1 receptor agonists and kidney protection. Medicina (Kaunas). 2019;55(6):233. doi: 10.3390/medicina55060233. DOI: https://doi.org/10.3390/medicina55060233

4. Tuttle KR, Bosch-Traberg H, Cherney DZI, Hadjadj S, Lawson J, Mosenzon O, et al. Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney Int. 2023;103(4):772-81. doi: 10.1016/j.kint.2022.12.028. DOI: https://doi.org/10.1016/j.kint.2022.12.028

5. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032-45. doi: 10.2215/CJN.11491116. DOI: https://doi.org/10.2215/CJN.11491116

6. Maselli DB, Camilleri M. Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity. Adv Exp Med Biol. 2021;1307:171-92. doi: 10.1007/5584_2020_496. DOI: https://doi.org/10.1007/5584_2020_496

7. Jalleh RJ, Rayner CK, Hausken T, Jones KL, Camilleri M, Horowitz M. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. Lancet Gastroenterol Hepatol. 2024;9(10):957-64. doi: 10.1016/S2468-1253(24)00188-2. DOI: https://doi.org/10.1016/S2468-1253(24)00188-2

8. Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. doi: 10.1016/j.molmet.2019.09.010. DOI: https://doi.org/10.1016/j.molmet.2019.09.010

9. Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, et al. GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol (Lausanne). 2021;12:721135. doi: 10.3389/fendo.2021.721135. DOI: https://doi.org/10.3389/fendo.2021.721135

10. Diz-Chaves Y, Herrera-Pérez S, González-Matías LC, Lamas JA, Mallo F. Glucagon-like peptide-1 (GLP-1) in the integration of neural and endocrine responses to stress. Nutrients. 2020;12(11):3304. doi: 10.3390/nu12113304. DOI: https://doi.org/10.3390/nu12113304

11. Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387(21):1923-34. doi: 10.1056/NEJMoa2210645. DOI: https://doi.org/10.1056/NEJMoa2210645

12. Long B, Pelletier J, Koyfman A, Bridwell RE. GLP-1 agonists: a review for emergency clinicians. Am J Emerg Med. 2024;78:89-94. doi: 10.1016/j.ajem.2024.01.010. DOI: https://doi.org/10.1016/j.ajem.2024.01.010

13. Nauck MA, Quast DR. Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6. Front Endocrinol (Lausanne). 2021;12:645566. doi: 10.3389/fendo.2021.645566. DOI: https://doi.org/10.3389/fendo.2021.645566

14. Pizzey FK, Hodges GJ. The effect of heat therapy on blood pressure and peripheral vascular function: a systematic review and meta-analysis. Exp Physiol. 2021;106(6):1317-34. doi: 10.1113/EP089424. DOI: https://doi.org/10.1113/EP089424

15. Aroda VR, Agyemang-Prempeh B, Blonde L, Brown RE, Frias JP, Gydesen H, et al. Safety and tolerability of semaglutide in the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes Obes Metab. 2023;25(5):1385-97. doi: 10.1111/dom.14990. DOI: https://doi.org/10.1111/dom.14990

16. Aldawsari M, Aljathlani S, Alshahrani F, Aljohar A, Alfadda AA. The efficacy of GLP-1 analogues on appetite restrictions, gastric emptying, food preference, and taste sensation among adults with obesity: systematic review of clinical trials. Diabetes Metab Syndr Obes. 2023;16:575-95. doi: 10.2147/DMSO.S387116. DOI: https://doi.org/10.2147/DMSO.S387116

17. Smits MM, Van Raalte DH. Corrigendum: safety of semaglutide. Front Endocrinol (Lausanne). 2021;12:786732. doi: 10.3389/fendo.2021.786732. DOI: https://doi.org/10.3389/fendo.2021.786732

18. Rico-Fontalvo J, Daza-Arnedo R, Pájaro-Gálvez N, Raad-Sarabia M, Yánez-Rodríguez T, Uparella-Gulfo D, et al. Kidney effects of glucagon-like peptide 1 (GLP-1): from molecular foundations to a pharmacophysiological perspective. J Bras Nefrol. 2024;46(4):e20240101. doi: 10.1590/2175-8239-JBN-2024-0101en. DOI: https://doi.org/10.1590/2175-8239-jbn-2024-0101en

19. Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754-62. doi: 10.1111/dom.14280. DOI: https://doi.org/10.1111/dom.14280

20. Gabe MBN, Breitschaft A, Knop FK, Hansen MR, Kirkeby K, Rathor N, et al. Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: a randomized controlled trial. Diabetes Obes Metab. 2024;26(10):4480-9. doi: 10.1111/dom.15802. DOI: https://doi.org/10.1111/dom.15802

21. Mahapatra MK, Karuppasamy M, Sahoo BM. Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: a narrative review. Pharm Res. 2022;39(6):1233-48. doi: 10.1007/s11095-022-03302-1. DOI: https://doi.org/10.1007/s11095-022-03302-1

22. Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610-9. doi: 10.1111/dom.13120. DOI: https://doi.org/10.1111/dom.13120

23. Mima A, Gotoda H, Lee R, Murakami A, Akai R, Lee S. Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: a systemic review and meta-analysis. Metabol Open. 2023;17:100236. doi: 10.1016/j.metop.2023.100236. DOI: https://doi.org/10.1016/j.metop.2023.100236

24. Marx N, Deanfield JE, Mann JFE, Arechavaleta R, Bain SC, Bajaj HS, et al. Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial. Circulation. 2025;151(23):1639-50. doi: 10.1161/CIRCULATIONAHA.125.074545. DOI: https://doi.org/10.1161/CIRCULATIONAHA.125.074545

25. Maretty L, Gill D, Simonsen L, Soh K, Zagkos L, Galanakis M, et al. Proteomic changes upon treatment with semaglutide in individuals with obesity. Nat Med. 2025;31(1):267-77. doi: 10.1038/s41591-024-03355-2. DOI: https://doi.org/10.1038/s41591-024-03355-2

26. Kommu S, Whitfield P. Semaglutide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.

27. Mahaffey KW, Tuttle KR, Arici M, Baeres FMM, Bakris G, Charytan DM, et al. Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. Eur Heart J. 2025;46(12):1096-108. doi: 10.1093/eurheartj/ehae613. DOI: https://doi.org/10.1093/eurheartj/ehae613

28. Theodorakis N, Nikolaou M. Integrated management of cardiovascular-renal-hepatic-metabolic syndrome: expanding roles of SGLT2is, GLP-1RAs, and GIP/GLP-1RAs. Biomedicines. 2025;13(1):135. doi: 10.3390/biomedicines13010135. DOI: https://doi.org/10.3390/biomedicines13010135

29. Tian S, Zhou S, Wu W, Lin Y, Wang T, Sun H, et al. GLP-1 receptor agonists alleviate diabetic kidney injury via β-klotho-mediated ferroptosis inhibition. Adv Sci (Weinh). 2025;12(4):e2409781. doi: 10.1002/advs.202409781. DOI: https://doi.org/10.1002/advs.202409781